Search research articles
Contact Us
Filters
Showing results (11-20 of 52) with videos related to
Page
of 6
Sort By:
Journal of Medicinal Chemistry
|
July 5, 2023
Expanding Chemical Probe Space: Quality Criteria for Covalent and Degrader Probes
Ingo V Hartung, Joachim Rudolph, Mary M Mader, et al.
International Journal of Pharmaceutics
|
July 10, 2013
Systemic in vitro and in vivo evaluation for determining the feasibility of making an amorphous solid dispersion of a B-Raf (rapidly accelerated fibrosarcoma) inhibitor
Yong Cui, Po-Chang Chiang, Edna F Choo, et al.
ACS Chemical Biology
|
December 27, 2023
Allosteric Inhibitors of the SARS-COV-2 Papain-like Protease Domain Induce Proteasomal Degradation of Its Parent Protein NSP3
Peter E Cockram, Benjamin T Walters, Aaron Lictao, et al.
Bioorganic & Medicinal Chemistry Letters
|
January 3, 2012
Pyrazolopyridine inhibitors of B-Raf(V600E). Part 3: an increase in aqueous solubility via the disruption of crystal packing
Steve Wenglowsky, David Moreno, Joachim Rudolph, et al.
Bioorganic & Medicinal Chemistry Letters
|
September 8, 2012
Pyrazolopyridine inhibitors of B-Raf(V600E). Part 4: rational design and kinase selectivity profile of cell potent type II inhibitors
Steve Wenglowsky, David Moreno, Ellen R Laird, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals
|
January 31, 2026
Preclinical translational physiologically based pharmacokinetic modeling for predicting human pharmacokinetics of proteolysis targeting chimeras: Case studies of vepdegestrant (ARV-471) and bavdegalutamide (ARV-110)
Ramakrishna Rachumallu, Jonathan Cheong, Gauri Deshmukh, et al.
Xenobiotica; the Fate of Foreign Compounds in Biological Systems
|
August 26, 2011
Preclinical assessment of novel BRAF inhibitors: integrating pharmacokinetic-pharmacodynamic modelling in the drug discovery process
Edna F Choo, Bruno Alicke, Jason Boggs, et al.
Bioorganic & Medicinal Chemistry Letters
|
December 27, 2011
Potent and selective pyrazolo[1,5-a]pyrimidine based inhibitors of B-Raf(V600E) kinase with favorable physicochemical and pharmacokinetic properties
Li Ren, Ellen R Laird, Alex J Buckmelter, et al.
ACS Medicinal Chemistry Letters
|
December 18, 2024
Heteroaryl Glutarimides and Dihydrouracils as Cereblon Ligand Scaffolds for Molecular Glue Degrader Discovery
Yuebiao Zhou, Star L Garrigues, Elisia Villemure, et al.
Bioorganic & Medicinal Chemistry Letters
|
June 28, 2016
Synthesis and evaluation of a series of 4-azaindole-containing p21-activated kinase-1 inhibitors
Wendy Lee, James J Crawford, Ignacio Aliagas, et al.
Page
of 6
Search research articles
Search
Showing results (11-20 of 52) with videos related to
Sort By:
Page
of 6
Journal of Medicinal Chemistry
|
July 5, 2023
Expanding Chemical Probe Space: Quality Criteria for Covalent and Degrader Probes
Ingo V Hartung, Joachim Rudolph, Mary M Mader, et al.
International Journal of Pharmaceutics
|
July 10, 2013
Systemic in vitro and in vivo evaluation for determining the feasibility of making an amorphous solid dispersion of a B-Raf (rapidly accelerated fibrosarcoma) inhibitor
Yong Cui, Po-Chang Chiang, Edna F Choo, et al.
ACS Chemical Biology
|
December 27, 2023
Allosteric Inhibitors of the SARS-COV-2 Papain-like Protease Domain Induce Proteasomal Degradation of Its Parent Protein NSP3
Peter E Cockram, Benjamin T Walters, Aaron Lictao, et al.
Bioorganic & Medicinal Chemistry Letters
|
January 3, 2012
Pyrazolopyridine inhibitors of B-Raf(V600E). Part 3: an increase in aqueous solubility via the disruption of crystal packing
Steve Wenglowsky, David Moreno, Joachim Rudolph, et al.
Bioorganic & Medicinal Chemistry Letters
|
September 8, 2012
Pyrazolopyridine inhibitors of B-Raf(V600E). Part 4: rational design and kinase selectivity profile of cell potent type II inhibitors
Steve Wenglowsky, David Moreno, Ellen R Laird, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals
|
January 31, 2026
Preclinical translational physiologically based pharmacokinetic modeling for predicting human pharmacokinetics of proteolysis targeting chimeras: Case studies of vepdegestrant (ARV-471) and bavdegalutamide (ARV-110)
Ramakrishna Rachumallu, Jonathan Cheong, Gauri Deshmukh, et al.
Xenobiotica; the Fate of Foreign Compounds in Biological Systems
|
August 26, 2011
Preclinical assessment of novel BRAF inhibitors: integrating pharmacokinetic-pharmacodynamic modelling in the drug discovery process
Edna F Choo, Bruno Alicke, Jason Boggs, et al.
Bioorganic & Medicinal Chemistry Letters
|
December 27, 2011
Potent and selective pyrazolo[1,5-a]pyrimidine based inhibitors of B-Raf(V600E) kinase with favorable physicochemical and pharmacokinetic properties
Li Ren, Ellen R Laird, Alex J Buckmelter, et al.
ACS Medicinal Chemistry Letters
|
December 18, 2024
Heteroaryl Glutarimides and Dihydrouracils as Cereblon Ligand Scaffolds for Molecular Glue Degrader Discovery
Yuebiao Zhou, Star L Garrigues, Elisia Villemure, et al.
Bioorganic & Medicinal Chemistry Letters
|
June 28, 2016
Synthesis and evaluation of a series of 4-azaindole-containing p21-activated kinase-1 inhibitors
Wendy Lee, James J Crawford, Ignacio Aliagas, et al.
Page
of 6